Physician

Samuel H Foster, MD

According to 2025 Medicare claims, Samuel Foster, MD (NPI: 1780665984) practices cardiology in the Lexington Park, MD market, with the plurality of this provider's patient population coming from Calvert, MD. This provider's primary affiliated billing organization is CALVERT INTERNAL MEDICINE GROUP PA (NPI: 1174682298; TIN: 521365400) and primary practice location at 20678-4044.

Foster's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,313 traditional Medicare patients, billed 6,298 HCPCS/CPT codes, and received $456,972 in Medicare payments. The top billing code was 93306 (Ultrasound of heart with color-depicted blood flow, rate, direction and valve function). Part D data shows 4,162 prescription claims across 546 beneficiaries totaling $1,044,022 in drug costs, led by Eliquis (Apixaban). DME data shows 24 claims. Open Payments data shows 4 records totaling $205. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $337,512 to $456,972. Similarly, Part D prescription costs have risen steadily, from $467,651 to $1,044,022. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $1,143 to $321.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,715	5,836	$337,512
2016	1,859	6,204	$329,797
2017	1,885	5,860	$313,472
2018	1,897	5,990	$299,592
2019	1,914	6,530	$322,665
2020	1,048	4,117	$294,062
2021	1,251	5,330	$335,942
2022	1,438	6,468	$500,688
2023	1,461	6,912	$560,592
2024	1,313	6,298	$456,972

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	289	1,983	$467,651
2016	352	2,413	$550,037
2017	370	2,724	$631,268
2018	401	2,887	$769,076
2019	403	2,901	$754,542
2020	391	2,959	$635,377
2021	421	3,129	$644,183
2022	431	3,289	$730,322
2023	446	3,571	$809,436
2024	546	4,162	$1,044,022

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	28	$1,142
2020	N/R	26	$181,772
2021	N/R	24	$180,724
2022	N/R	24	$185,079
2023	N/R	24	$192,268
2024	N/R	24	$195,373

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	582	607	$131
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	802	1,342	$90
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	270	336	$13
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	561	615	$10
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	203	263	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	268	20,722	$392,414
Xarelto	Rivaroxaban	129	10,144	$181,192
Bosentan	Bosentan	12	360	$112,934
Entresto	Sacubitril/Valsartan	41	2,910	$61,959
Farxiga	Dapagliflozin Propanediol	34	2,280	$41,644

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7686	Treprostinil, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, 1.74 mg	N	N/R	12	$195,088
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	N/R	12	$285

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	4	$205	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Samuel H. Foster, MD?

Tedicare shows public-source Medicare data for Samuel H. Foster, MD (NPI 1780665984), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Samuel H. Foster, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Samuel H. Foster, MD?

Samuel H. Foster, MD is linked to CALVERT INTERNAL MEDICINE GROUP PA (billing NPI 1174682298) in the available physician profile data.

Does Samuel H. Foster, MD have Open Payments data?

Samuel H. Foster, MD has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.